Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients with Multidrug-Resistant Tuberculosis and HIV/AIDS
Document Type
Article
Roles
Author
Publication Date
1-1-2022
Publication Title
Journal of Acquired Immune Deficiency Syndromes
DOI
10.1097/QAI.0000000000002940
Recommended Citation
O'Donnell, M., Padayatchi, N., Wolf, A., Zelnick, J. R., Daftary, A., Orrell, C., Nimmo, C., Baldwin, M., Boodhram, R., Maharaj, B., Amico, K., Naidoo, K., & Friedland, G. (2022). Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients with Multidrug-Resistant Tuberculosis and HIV/AIDS. Journal of Acquired Immune Deficiency Syndromes, 90 (3), 325-332. https://doi.org/10.1097/QAI.0000000000002940
